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Background
Our outdoor patient clinic in Salzburg (Austria) com-
prises 170 HIV-infected patients. Since 2004 our labora-
tory has been using Cobas TaqMan 48 real time PCR
analyser (Roche) for detection and quantification of HIV-
1 RNA. To date we could identify four patients who
remained undetectable (3/4) or who presented with very
low viremia (<200 copies per ml) while receiving no
antiretroviral therapy at all.
Methods
To evaluate this issue, further analyses of the HIV-1 RNA
in plasma were undertaken using Cobas Amplicor version
1.5, and the Abbott m2000 system. For patients 1 and 2,
virus was isolated by co-cultivation of patients' PBMCs
with uninfected donor PBMCs and the nucleic acid
sequences of the gag, pol, and env genes of both virus iso-
lates were determined. For patients 3 and 4, gag and pol
genes were sequenced directly from PCR amplicons. All
sequences were subsequently subtyped using standard
phylogenetic analysis tools. Finally, a positive control
amplicon of Cobas TaqMan was compared to the
sequences of our patients.
Summary of results
All four patients showed detectable plasma viral loads
ranging from 1,700 copies per ml to 22,000 copies per ml
using the Abbott m2000 system. With Cobas Amplicor
only one patient remained undetectable, while three oth-
ers had similar virus load results as obtained with the
Abbott system. We found three different HIV subtypes: B,
F1 and A1 (twice), which according to manufacturer's
instructions all should have been recognized by Cobas
TaqMan Assay. The analysis of the Cobas TaqMan ampli-
con revealed numerous mismatches to the patients gag
gene sequences in the putative 3'-primer binding region
which in combination with the real-time format may be
responsible for the observed misquantification. (Table 1.)
Conclusion
In the face of the severe consequences for therapeutic deci-
sions and patient counseling, the observed rate of mis-
quantifications in our patient cohort by Cobas TaqMan
HIV-1 is unacceptable. Misquantifications can not be
assigned to a rare subtype but occur with different virus
strains. There is an urgent need for refinement of the
Cobas TaqMan. In addition, these findings shed a differ-
ent light concerning the definition of so-called elite con-
trollers in clinical practice.
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Patient No. HIV Subtype Analysis Date Cobas TaqMan Real Time 
PCR [cop/ml]
Abbott m2000 PCR 
[cop/ml]
Cobas Amplicor Version 1.5 
PCR [cop/ml]
1 F1 13.09.06 <40 21000
25.09.06 <40 2200 <400 (03.01.07)
2 A1 25.01.07 184 13000 11900
02.06.06 98 22000 18600 (16.02.07)
3 B 17.03.08 <40 12000 7280
31.03.08 <40 21000 11500
4 A1 05.05.08 <40 1700 2380Page 2 of 2
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